Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages

  Bertaglia, Valentina ^a   Tucci, Marcello ^a   Fiori, Cristian ^a   Aroasio, Emiliano ^b   Poggio, Massimiliano ^a   Buttigliero, Consuelo ^a   Grande, Susanna ^a   Saini, Andrea ^a   Porpiglia, Francesco ^a   Berruti, Alfredo ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Hormonal therapy; Prognosis; Prostate cancer; Testosterone

Indexed keywords

BICALUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DRUG EFFICACY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRESCRIPTION; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

HORMONAL THERAPY; PROGNOSIS; PROSTATE CANCER; TESTOSTERONE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84883466108     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.01.002     Document Type: Article

References (19)

1. N. Sharifi, J.L. Gulley, W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2005 238 244
2. N. Mottet, J. Bellmunt, M. Bolla EAU guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
3. M.J. Wheeler, A. D'Souza, J. Matadeen Ciba Corning ACS:180 testosterone assay evaluated Clin Chem 42 1996 1445 1449
4. M.G. Oefelein, A. Feng, M.J. Scolieri Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
5. M. Perachino, V. Cavalli, F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? Br J Urol 105 2010 648 651
6. J. Morote, J. Planas, C. Ramirez Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk BJU Int 105 2010 481 484
7. B. Tombal The importance of testosterone control in prostate cancer Eur Urol 6 2007 834 839
8. C.C. Schulman, J. Irani, J. Morote Testosterone measurement in patients with prostate cancer Eur Urol 258 2010 65 74
9. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Prostate Cancer Trialists Collaborative Group [No authors listed] Lancet 355 2000 1491 1498
10. R.L. Prentice Surrogate and mediating endpoints: current status and future directions J Natl Cancer Inst 101 2009 216 217
11. J.S. De Bono, C.J. Logothetis, A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
12. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
13. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
14. M.R. Smith, F. Kabbinavar, F. Saad Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925
15. G.W. Bong, T.E. Keane Salvage options for biochemical recurrence after primary therapy for prostate cancer Can J Urol 14 Suppl 1 2007 2 9
16. J. Morote, A. Orsola, J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295
17. W. Rosner, H. Vesper Endocrine Society; American Association For Clinical Chemistry; American Association Of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society For Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation Of America; North American Menopause Society; Pediatric Endocrine Society Toward excellence in testosterone testing: A consensus statement J Clin Endocrinol Metab 92 2007 4542 4548
18. L.P. Ly, G. Sartorius, L. Hull Accuracy of calculated free testosterone formulae in men Clin Endocrinol 73 2010 382 388
19. J.G. Middle Dehydroepiandrostenedione sulphate interferes in many direct immunoassays for testosterone Ann Clin Biochem 44 2007 173 177